SEA-TGT
- Generic Name
- SEA-TGT
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Sasanlimab Prefilled syringe
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT04585815
- Locations
- 🇨🇳
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1
Terminated
- Conditions
- Non-small Cell Lung CancerGastric CarcinomaGastroesophageal Junction CarcinomaClassical Hodgkin LymphomaDiffuse Large B-cell LymphomaPeripheral T-cell LymphomaCutaneous MelanomaHead and Neck Squamous Cell CarcinomaBladder CancerOvarian Cancer
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT04254107
- Locations
- 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath